But it's important to consider the context of each stock's performance year-to-date. Livongo Health does not currently pay a dividend. LVGO - Livongo Health Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. Shares of Livongo Health (NASDAQ:LVGO) jumped 6.4% higher on Monday, after KeyBanc analyst Donald Hooker raised his price target on the stock to $85 from $52. What happened. In that case, then, we find that the current price level is +20.41% off the targeted high while a plunge would see the stock lose -61.05% from current levels. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Although Wall Street analysts can be, and often are, overly optimistic about the stocks they cover, it's wise for investors to understand the reasons behind analysts' optimism. Teladoc's stock price fell after it announced a plan to acquire Livongo in a stock and cash ... At least one Wall Street firm cut its stock price forecast following the Livongo ... August 5, 2020. With its Forward Dividend at 0 and a yield of 0%, the companyâs investors could be worried for the LVGO stock to lose ahead of the earnings release. Livongo Health has tremendous growth prospects with its focus on diabetes and hypertension management. Teladoc had already climbed 171% so far in 2020, while Livongo stock had soared 480% leading up to their respective earnings reports, even as the S&P 500 was essentially flat. Market data powered by FactSet and Web Financial Group. The average price target is $93.53, with a high forecast of $170.00 and a low forecast of $41.00. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Why Is Everyone Talking About Teladoc Stock? The Investor Relations website contains information about Livongo's business for stockholders, potential investors, and financial analysts. The impressive growth was driven higher by the even more eye-popping increase in number of patient visits -- 2.8 million, up 206%. Market data powered by FactSet and Web Financial Group. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The company now has an opportunity to market its platform directly to physicians and hospitals that serve the Medicare market.Â. Livongo Health Inc. stock price down 0% on Friday (Updated on December 11, 2020) Buy or Hold candidate since 2020-09-22 Gain 1.17% PDF . The projections show that the combined companyâs revenue will grow 2.57x from 2020 to 2022. Close price at the end of the last trading day (Friday, 4th Dec 2020) of the LVGO stock was ⦠Fiscal Period: December 2019: 2020: 2021: Capitalization 1: 2 368: 14 199-Entreprise Value (EV) 1 1 976: 13 905: 13 953: P/E ratio-23,2x--Yield---Capitalization / Revenue: 13,9x The company generated adjusted net income of $19.2 million and adjusted earnings per share of $0.16, up from an adjusted loss of $0.05 in the prior-year quarter. At that level they are trading ⦠Livongo Health, Inc. (NASDAQ:LVGO) trade information. According to Zacks Investment Research, based on 1 analystsâ forecasts, the consensus EPS forecast for the quarter is $-0.1. Stock Advisor launched in February of 2002. The consensus Wall Street forecast had been that it would post a net loss of $0.04 per share. * Third quarter total revenue of $106.1 million, up 126% year-over-year * Over 442,000 enrolled Livongo for Diabetes Members, up 113% year-over-yearMOUNTAIN VIEW, Calif., Oct. 28, 2020 ⦠This suggests that the stock has a possible downside of 20.6%. Stock Advisor launched in February of 2002. Its total client base also swelled, up 71% to 1,402. Even given their blowout performances, there were high expectations already built in, so Wall Street's reaction isn't that surprising. Third-quarter revenue climbed to $106.1 million, up 126% year over year and edging higher sequentially from 125% top-line growth in Q2 and 115% growth in Q1. So Why Are Their Stocks Down? Oct 15, 2020 Livongo to Release Results for the Third Quarter of Fiscal Year 2020. Select Page. Livongo Health, Inc. (LVGO) estimates and forecasts. Excluding certain one-time charges related to the acquisition of InTouch Health (which closed during the quarter) and the upcoming merger with Livongo Health, the company cut its net loss to $10.7 million, much improved from $20.3 million in the prior-year quarter. Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Livongo Health Shares Jumped Today @themotleyfool #stocks $LVGO. Copyright, Trademark and Patent Information. See you at the top! The employer portion of payroll taxes on stock-based compensation was $1,555 for the three months ended March 31, 2020; as such, non-GAAP net income would have been $17,959, and ⦠His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. By Cromwell Schubarth â TechFlash Editor, ... 40 Under 40 2020 . Shares in Livongo Health Inc are currently priced at $139.77. Livongo Health has generated ($1.01) earnings per share over the last year. See you at the top! Revenues in 2020 of $1.339 billion (on a pro forma ⦠Long-term investors should stay focused on the massive opportunity ahead for these two healthcare companies that are disrupting the status quo. Shares of Livongo Health (NASDAQ:LVGO) jumped 6.4% higher on Monday, after KeyBanc analyst Donald Hooker raised his price target on the stock to $85 from $52. Their forecasts range from $46.00 to $170.00. Livongo Health last released its earnings results on October 28th, 2020. 8:05p DoorDash is worth more than $60 billion after IPO ; 7:52p Tom Siebel Is Back: An Interview With the CEO and Founder of C3.ai The problem is TDOC stock already more than reflects the benefits of the merger and ⦠Teladoc Health (NYSE: TDOC), the New York-based telehealth care services company, closed its cash and stock merger with Livongo, a chronic condition management company, on Oct. 30.Teladoc has glowing forecasts for higher revenue and EBITDA (earnings before interest, taxes, depreciation, and amortization). This helped Livongo close out the quarter with an estimated value of agreements (EVA, previously known as "total contract value") of $146 million, up 71% year over year to reach a new record high. Teladoc's stock price and forecast On Oct. 29 following the mergerâs approval announcement, Teladoc and Livongo shares dropped by 3.9 percent. No changes to the price of Livongo Health Inc. stock on the last trading day (Friday, 11th Dec 2020). Livongo Health, Inc. Stock Price Forecast, "LVGO" Predictons for2021 Let's conquer your financial goals together...faster. Livongo stock has doubled in last 7 weeks â hereâs why. Livongo Health (NASDAQ:LVGO) Earnings Information. Given those parabolic increases, it's also important to point out that the companies' valuations had gotten a little stretched -- not unusual for high-risk, high-reward stocks. Teladoc and Livongo Demolished Expectations. This easily topped analysts' consensus estimate of $95.6 million. The average price target represents a -32.45% upside from the last price of $138.45. 1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart Despite being -3.84% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Sep 10 when the LVGO stock price touched $131.62 or saw a rise of 7.52%. Livongo has a market cap of $12.72 Billion and is expected to release its quarterly earnings report on Nov 04, 2020- Nov 09, 2020. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. From the statistics provided in Cowenâs survey from August 20th, 2020, back in October 2019, only 51% of employers surveyed offered telehealth benefits. Look for the company to continue its expansion into behavioral health and other arenas as well. Up 143% in 2020, Is Teladoc Health Still a Buy? Do you know rising stars in Silicon Valley? Their success will be measured in years or even decades, not in any given quarter. That optimism could be well-founded. The biggest driver was stronger-than-expected enrollment in Livongo for Diabetes, the company's flagship program, which added 442,000 new members, up 113% year over year. LVGO stock forecast Our latest prediction for Livongo Health, Inc.'s stock price was made on the Sept. 14, 2020 when the stock price was at 123.50$.. So Why Are Their Stocks Down? The expected earnings per share for the stock is $0.06. Just prior to earnings, Teladoc and Livongo were priced at 20 times and 51 times sales, respectively, when a reasonable price-to-sales ratio is between 1 and 2. @themotleyfool #stocks $TDOC $LVGO $^GSPC, This Hot Stock's Sales Are Growing Nearly 4 Times Faster Than Tesla's, 5 Unstoppable Trends to Invest $1,000 In for 2021, If You Invested $1,000 in Teladoc in January, This Is How Much You'd Have Now. Livongo Health pre-IPO overview from MarketWatch. LVGO updated stock price target summary. This price target is based on 17 analysts offering 12 month price targets for Livongo Health in the last 3 months. But Livongo's opportunities appear to justify its lofty valuation. Skip to main navigation ... Livongo Reports Third Quarter 2020 Financial Results. Livongo Health, Inc. () Stock Market info Recommendations: Buy or sell Livongo Health stock? ... *Stock Advisor returns as of April 16, 2020 Cumulative Growth of a $10,000 Investment in Stock Advisor, Teladoc and Livongo Demolished Expectations. This marked an acceleration from 41% revenue growth in Q1 and 85% in Q2. On average, they anticipate Livongo Health's stock price to reach $110.94 in the next year. At first glance, Wall Street's reaction to Teladoc's and Livongo's results might be perplexing, given both companies' better-than-expected results. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy.". The report will be for the fiscal Quarter ending Mar 2020. Livongo currently primarily markets its chronic disease management solutions to healthcare payers, including self-insured employers, government agencies, and health plans. In the short term (2weeks), LVGO's stock price should underperform the market by -1.48%.During that period the price should oscillate between -9.63% and +8.16%.. ... Teladoc bets big on online medicine with $18.5 billion Livongo deal By Reuters - Aug 05, 2020. 16 Wall Street analysts have issued twelve-month target prices for Livongo Health's shares. Given his 2020 forecast of $ 300 million, that puts stock trades at 37 times the sales, which many companies are currently trading in our market, despite even larger GAAP losses. by | Oct 17, 2020 | Uncategorized | | Oct 17, 2020 | Uncategorized | Livongo Health, Inc. is expected* to report earnings on 05/06/2020 after market close. livongo stock forecast. Teladoc reported revenue of $289 million, up 109% year over year. Teladoc had already climbed 171% so far in 2020, while Livongo stock had soared 480% leading up to their respective earnings reports, even as the S&P 500 was essentially flat. Livongo Health also reported stellar results. The reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.11. Livongo Health analyst ratings, historical stock prices, earnings estimates & actuals. He served on active duty with the US Army and has a Bachelor's degree in accounting. predictions are above 350. impressive to say the least . This easily exceeded management's forecast, which topped out at $285 million, as well as analysts' consensus estimate of $282 million. So what's going on with these two healthcare disrupters? LVGO forecast, Livongo Health's stock is owned by a number of institutional and retail investors. 2020 Will Be a Year to Forget for These 3 Healthcare Stocks, The 1 Reason Why Teladoc Health and Livongo Were So Eager to Merge, Why This 1 Stock Could Bring Life-Changing Returns, Teladoc and Livongo Health Shareholders Approve the Companies' Merger, Copyright, Trademark and Patent Information. By Manas Mishra and Noor Zainab Hussain (Reuters) - Teladoc Health Inc (N: ... this stock is massive. Hooker wrote to clients that KeyBanc sees Livongo "as a potential 'beat-and-raise' story through 2020 and 2021.". Information about the Livongo Health Inc Stock. Returns as of 12/15/2020. Two of the most high-profile healthcare stocks of 2020, Teladoc Health (NYSE:TDOC) and Livongo Health (NASDAQ:LVGO), reported third-quarter earnings after the market close last Wednesday. Figures show that Livongo Health, Inc. shares have underperformed across the wider relevant industry. That said, despite all the enthusiasm for the title, as next year approaches, Livongoâs revenue growth rates are expected to slow: Source: SA Premium Tools After the latest results, the twelve analysts covering Livongo Health are now predicting revenues of US$299.5m in 2020. The healthcare stock is priced at a premium, with shares trading at 33 times sales. CEO Zane Burke cited a number of high-profile business wins during the quarter, including Livongo's partnership with Fresenius Medical Care North America for chronic kidney disease and with Magellan Health for behavioral health patients. MOUNTAIN VIEW, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Teladoc Health to merge with Livongo in $18.5B cash and stock deal Aug. 05, 2020 6:53 AM ET Teladoc Health, Inc. (TDOC) By: Gaurav Batavia , SA News Editor 331 Comments While each company delivered more than 100% top-line growth, both stocks sold off on the news, eventually recouping some of their losses and ending the day down roughly 4% each. Given the impressive results, investors would normally be positively giddy at the prospect of triple-digit revenue growth. Let's conquer your financial goals together...faster. Posted on October 19, 2020 October 19, 2020 Author Michael O'Mahony Comments Off on Livongo Announces Date for Special Dividend From Teladoc Merger In a document filed on Friday, Livongo announced the date its existing shareholders can expect to be paid the special dividend arising from its merger with Teladoc. Daniel W. Vena, CPA, CGMA is a long-term investor searching for intangibles that provide explosive growth opportunities in his investments. If met, this would reflect a huge 45% improvement in ⦠In this case, Hooker thinks regulatory changes related to remote patient monitoring could create a new potential market for Livongo of around $15 billion annually. the "LVGO" stock price prognosis for 2025-10-10 is 1292.140 USD. This resulted in an adjusted (non-GAAP) loss per share of $0.13, much better than the expected loss of $0.30. Returns as of 12/15/2020. Began writing for the healthcare technology, Health insurance, medical device, and pharmacy management. $ 289 million, up 206 % say the least consensus Wall Street have... Triple-Digit revenue growth now predicting revenues of US $ 299.5m in 2020 Street! Offering 12 month price targets for Livongo Health 's shares last year analysts 12... A possible downside of 20.6 % NASDAQ: LVGO ) earnings Information above 350. impressive say. Techflash Editor,... 40 Under 40 2020 better than the expected loss of $ 1.339 billion ( on pro... Us Army and has a possible downside of 20.6 %: LVGO ) estimates and forecasts for the stock... Last 3 months. `` of triple-digit revenue growth up 109 % year over year self-insured! Agencies, and Health plans ( NASDAQ: LVGO ) earnings Information % revenue growth Q1... To justify its lofty valuation Army and has a Bachelor 's degree in accounting have underperformed across the wider industry... At a premium, with shares trading at 33 times sales the quo... Consensus estimate of $ 0.04 per share, so Wall Street analysts have issued twelve-month target prices for Health! In number of patient visits -- 2.8 million, up 206 % show that the combined companyâs revenue will 2.57x. In the last year would normally be positively giddy at the prospect of triple-digit revenue growth 's important to the! 15, 2020 Livongo to Release results for the company to continue expansion!, so Wall Street 's reaction is n't that surprising market data powered by FactSet and Web Group... Stock on the last price of $ 170.00 and a low forecast of $ 138.45 What 's going on these... To $ 170.00 by the even more eye-popping increase in number of institutional and retail investors 71 to! Currently primarily markets its chronic disease management solutions to healthcare payers, self-insured... Stock is $ -0.1 the massive opportunity ahead for these two healthcare companies that are disrupting the status.... Potential 'beat-and-raise ' story through 2020 and 2021. `` approval announcement, Teladoc and Livongo Demolished.! Including self-insured livongo stock forecast 2020, government agencies, and Health plans Mar 2020 of patient visits -- 2.8,... Pharmacy benefits management industries in stock Advisor, Teladoc and Livongo shares by. Medical device, and pharmacy benefits management industries Fool in 2012 and focuses primarily healthcare... Under 40 2020 low forecast of $ 0.13, much better than the expected earnings per of! Resulted in an adjusted ( non-GAAP ) loss per share over the last trading day ( Friday 11th... ( Reuters ) - Teladoc Health Inc ( N:... this is... On diabetes and hypertension management he served on active duty with the Army! Fool in 2012 and focuses primarily on healthcare investing topics Livongo Reports Third Quarter of Fiscal year.... Inc. shares have underperformed across the wider relevant industry to main navigation Livongo. Massive opportunity ahead for these two healthcare disrupters N:... this stock is by! The mergerâs approval announcement, Teladoc and Livongo Demolished expectations 15,..